{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T19:08:10Z","timestamp":1788808090755,"version":"build-2803163510"},"reference-count":18,"publisher":"Oxford University Press (OUP)","issue":"9","license":[{"start":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T00:00:00Z","timestamp":1787011200000},"content-version":"vor","delay-in-days":12,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,8,6]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Colorectal cancer (CRC) can be effectively treated with fluoropyrimidine chemotherapy doublets. The triplet chemotherapy program, FOLFOXIRI, is more effective than a doublet in randomized trials. We combined this triplet with the anti-epidermal growth factor receptor (EGFR) antibody, panitumumab, as first-line therapy in the appropriately targeted population: left-sided, RAS wild-type metastatic CRC.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A multicenter trial was conducted with the AGICC (Academic GI Cancer Consortium) group. Patients with stage IV or unresectable, left-sided, Rat Sarcoma Virus oncogene (RAS) wild-type CRC were eligible if they had measurable disease, adequate organ function, and Perfromance Status (PS) 0-1. Consented patients were treated with modified FOLFOXIRI and panitumumab every 2\u2009weeks until progression or toxicity. CT scans were performed every 8\u2009weeks. The primary endpoint was response rate by Response Evaluation Criteria in Solid Tumors (RECiST) v1.1, with an expectation of an RR \u226585%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Twenty-nine patients were enrolled and 27 were treated. A total of 430 cycles were given, including 7 patients with the maximum of 24 cycles (median 18, range 3-24). Best response included 2 CR, 18 PR, and 6 SD (RR 74%). One patient progressed at the time of first assessment. Grade 3+ toxicity included neutropenia, diarrhea, rash, hypomagnesemia, and hypokalemia, similar to prior reports. No patient had grade 5 toxicity. Median progression-free survival (PFS) was 17.0\u2009months, and overall survival was not reached but exceeded 36\u2009months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>In this small US multicenter study, utilizing FOLFOXIRI with an anti-EGFR antibody for appropriately selected patients, we note that the response rates and PFS values are among the highest reported in stage IV colon cancer.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>ClinicalTrials.gov identifier<\/jats:title>\n                    <jats:p>NCT04169347.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyag320","type":"journal-article","created":{"date-parts":[[2026,8,15]],"date-time":"2026-08-15T12:47:04Z","timestamp":1786798024000},"source":"Crossref","is-referenced-by-count":0,"title":["FOLFOXIRI plus panitumumab for left-sided RAS-wild-type metastatic colorectal cancer"],"prefix":"10.1093","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9893-1529","authenticated-orcid":false,"given":"Howard S","family":"Hochster","sequence":"first","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ 08901,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrick J","family":"Blatchford","sequence":"additional","affiliation":[{"name":"Blatchford Analytics , Denver, CO 80201,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey","family":"Stein","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ 08901,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jill","family":"Lacy","sequence":"additional","affiliation":[{"name":"Yale Cancer Center , New Haven, CT 06520,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4305-5701","authenticated-orcid":false,"given":"Anup","family":"Kasi","sequence":"additional","affiliation":[{"name":"University of Kansas , Kansas City, KS 66160,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4213-8847","authenticated-orcid":false,"given":"Patrick M","family":"Boland","sequence":"additional","affiliation":[{"name":"Rutgers Cancer Institute, New Brunswick, NJ 08901,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philp","family":"Gold","sequence":"additional","affiliation":[{"name":"Swedish Cancer Institute , Seattle, WA 98122,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aaron J","family":"Scott","sequence":"additional","affiliation":[{"name":"University of Arizona , Tucson, AZ 85719,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Oberstein","sequence":"additional","affiliation":[{"name":"NYU Perlmutter Cancer Center , New York, NY 10023,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Cusnir","sequence":"additional","affiliation":[{"name":"Mt Sinai Medical Center , Miami, FL 33140,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kate","family":"Rouse","sequence":"additional","affiliation":[{"name":"Criterium Inc. Saratoga Springs, NY 12866,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Mallalieu","sequence":"additional","affiliation":[{"name":"Criterium Inc. Saratoga Springs, NY 12866,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anwaar","family":"Saeed","sequence":"additional","affiliation":[{"name":"UPMC , Pittsburgh, PA 15232,","place":["United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"For the AGICC Group","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,18]]},"reference":[{"key":"2026090714312577300_oyag320-B1","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"2026090714312577300_oyag320-B2","doi-asserted-by":"crossref","first-page":"3677","DOI":"10.1200\/JCO.2008.20.5278","article-title":"Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapy","volume":"27","author":"Kopetz","year":"2009","journal-title":"J Clin Oncol"},{"key":"2026090714312577300_oyag320-B3","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1200\/JCO.2005.07.113","article-title":"Phase III randomized trial of FOLFIRI versus FOLFOX4 in the treatment of advanced colorectal cancer: a multicenter study of the gruppo oncologico dell\u2019Italia meridionale","volume":"23","author":"Colucci","year":"2005","journal-title":"JCO"},{"key":"2026090714312577300_oyag320-B4","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa032691","article-title":"Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer","volume":"350","author":"Hurwitz","year":"2004","journal-title":"N Engl J Med"},{"key":"2026090714312577300_oyag320-B5","doi-asserted-by":"crossref","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","article-title":"Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study","volume":"26","author":"Saltz","year":"2008","journal-title":"J Clin Oncol"},{"key":"2026090714312577300_oyag320-B6","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","article-title":"Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer","volume":"360","author":"Van Cutsem","year":"2009","journal-title":"N Engl J Med"},{"key":"2026090714312577300_oyag320-B7","doi-asserted-by":"crossref","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","article-title":"Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study","volume":"28","author":"Douillard","year":"2010","journal-title":"JCO"},{"key":"2026090714312577300_oyag320-B8","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1200\/JCO.2006.09.0928","article-title":"Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the gruppo oncologico Nord ovest","volume":"25","author":"Falcone","year":"2007","journal-title":"J Clin Oncol"},{"key":"2026090714312577300_oyag320-B9","doi-asserted-by":"crossref","first-page":"1609","DOI":"10.1056\/NEJMoa1403108","article-title":"Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer","volume":"371","author":"Loupakis","year":"2014","journal-title":"N Engl J Med"},{"key":"2026090714312577300_oyag320-B10","doi-asserted-by":"crossref","first-page":"5s","DOI":"10.1200\/jco.2014.32.18_suppl.lba3","article-title":"CALGB\/SWOG 80405: Phase III trial of irinotecan\/5-FU\/leucovorin (FOLFIRI) or oxaliplatin\/5-FU\/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the Colon or rectum (MCRC)","volume":"32","author":"Venook","year":"2014","journal-title":"J Clin Oncol"},{"key":"2026090714312577300_oyag320-B11","doi-asserted-by":"crossref","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","article-title":"FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial","volume":"15","author":"Heinemann","year":"2014","journal-title":"Lancet Oncol"},{"key":"2026090714312577300_oyag320-B12","doi-asserted-by":"crossref","first-page":"3504","DOI":"10.1200\/JCO.2016.34.15_suppl.3504","article-title":"Impact of primary (1\u00b0) tumor location on overall survival (OS) and progression-free survival (PFS) in patients (pts) with metastatic colorectal cancer (mCRC): analysis of CALGB\/SWOG 80405 (alliance)","volume":"34","author":"Venook","year":"2016","journal-title":"JCO"},{"key":"2026090714312577300_oyag320-B13","doi-asserted-by":"crossref","first-page":"S344","DOI":"10.1016\/S0959-8049(16)30972-8","article-title":"AIO-KRK-0109: a randomized phase II trial of panitumumab plus FOLFOXIRI or FOLFOXIRI alone as 1st-line treatment in RAS-wild-type metastatic colorectal cancer (mCRC)","volume":"51","author":"Martens","year":"2015","journal-title":"Eur J Cancer (1965)"},{"key":"2026090714312577300_oyag320-B14","doi-asserted-by":"crossref","first-page":"2062","DOI":"10.1093\/annonc\/mdt165","article-title":"FOLFOXIRI in combination with panitumumab as first-line treatment in quadruple wild-type (KRAS, NRAS, HRAS, BRAF) metastatic colorectal cancer patients: a phase II trial by the gruppo oncologico Nord ovest (GONO)","volume":"24","author":"Fornaro","year":"2013","journal-title":"Ann Oncol"},{"key":"2026090714312577300_oyag320-B15","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1200\/JCO.2018.36.15_suppl.3509","article-title":"mFOLFOXIRI\u2009+\u2009panitumumab vs FOLFOXIRI as first-line treatment in patients with RAS wt CRC \u2013 randomized phase 2 AIO trial","volume":"36","author":"Geissler","year":"2018","journal-title":"JCO"},{"key":"2026090714312577300_oyag320-B16","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1001\/jama.2023.4428","article-title":"Panitumumab vs bevacizumab added to standard first-line chemotherapy and overall survival among patients with RAS wild-type, Left-Sided metastatic colorectal cancer: a randomized clinical trial","volume":"329","author":"Watanabe","year":"2023","journal-title":"JAMA"},{"key":"2026090714312577300_oyag320-B17","doi-asserted-by":"crossref","first-page":"2878","DOI":"10.1200\/JCO.22.00839","article-title":"Upfront modified fluorouracil, leucovorin, oxaliplatin, and irinotecan plus panitumumab versus fluorouracil, leucovorin, and oxaliplatin plus panitumumab for patients with RAS\/BRAF Wild-Type metastatic colorectal cancer: the phase III TRIPLETE study by GONO","volume":"140","author":"Rossini","year":"2022","journal-title":"J Clin Oncol"},{"key":"2026090714312577300_oyag320-B18","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1200\/JCO-25-01337","article-title":"Upfront modified FOLFOXIRI plus panitumumab for RAS\/BRAF Wild-Type metastatic colorectal cancer: Final results of the phase III TRIPLETE study","volume":"44","author":"Conca","year":"2026","journal-title":"J Clin Oncol"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyag320\/70684034\/oyag320.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag320\/70684034\/oyag320.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/31\/9\/oyag320\/70684034\/oyag320.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T18:31:34Z","timestamp":1788805894000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyag320\/8763694"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,6]]},"references-count":18,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,8,6]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyag320","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"value":"1083-7159","type":"print"},{"value":"1549-490X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,9]]},"published":{"date-parts":[[2026,8,6]]},"article-number":"oyag320"}}